Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 791 across all filing types
Latest filing 2025-10-24 Regulatory Filings
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
NANOBIOTIX annonce des mises à jour sur le programme clinique de JNJ-1900 (NBTXR3) à la suite du transfert de sponsorship et du contrôle opérationnel de l’essai de Phase 3 en cours dans le cancer de l
Regulatory Filings Classification · 95% confidence The document is a press release from Nanobiotix regarding updates to their clinical trial program (JNJ-1900/NBTXR3) following a transfer of sponsorship and operational control to Johnson & Johnson. It provides specific details on the status of the NANORAY-312 Phase 3 trial and future communication expectations. As this is a corporate announcement regarding business operations and clinical trial status, it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement that does not fit into more specific categories like Earnings Release or M&A.
2025-10-24 French
Voting Rights and Shares Capital of the Company
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a press release titled 'VOTING RIGHTS AND SHARES CAPITAL OF THE COMPANY'. It explicitly references French Commercial Code articles L.233-8 II and AMF General Regulation 223-16, which mandate the periodic disclosure of the total number of shares and voting rights. This type of disclosure is a standard regulatory requirement for listed companies to inform the market of their capital structure and voting rights, which falls under the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-10-15 English
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
Share Issue/Capital Change Classification · 95% confidence The document is a monthly disclosure required by French financial regulations (AMF) regarding the total number of shares and voting rights. This type of filing is a standard regulatory disclosure for companies listed on Euronext Paris. It does not fit into specific categories like 'Annual Report' or 'Earnings Release', and since it is a recurring regulatory requirement for share capital transparency, it falls under the 'Regulatory Filings' (RNS) category.
2025-10-15 French
NANOBIOTIX annonce les premières données de Phase 1 évaluant JNJ-1900 (NBTXR3) chez des patients atteints de cancer de l’œsophage
Regulatory Filings Classification · 95% confidence The document is a press release issued by Nanobiotix announcing clinical trial results (Phase 1 data for JNJ-1900 in esophageal cancer) presented at the ASTRO 2025 congress. It provides key highlights, safety data, and efficacy metrics (DCR, ORR). It does not constitute a full financial report, a transcript, or a regulatory filing of a specific form type, but rather an initial announcement of periodic clinical findings, which falls under the 'Earnings Release' category in the context of biotech/pharma companies reporting clinical milestones as their primary 'earnings' or performance updates.
2025-10-01 French
NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer
Earnings Release Classification · 95% confidence The document is a press release issued by Nanobiotix announcing clinical trial results (Phase 1 study of JNJ-1900). It details safety, feasibility, and efficacy data presented at a medical conference (ASTRO). It does not fit into financial reporting categories like 10-K or IR, nor is it a simple report publication announcement. As it is a general corporate announcement regarding clinical progress, it falls under the 'Regulatory Filings' (RNS) category as the fallback for miscellaneous corporate news. Q4 2025
2025-10-01 English
RAPPORT FINANCIER SEMESTRIEL
Interim / Quarterly Report Classification · 100% confidence The document is titled 'RAPPORT FINANCIER SEMESTRIEL' (Interim Financial Report) for the period ending June 30, 2025. It contains a detailed summary, management discussion and analysis (Rapport semestriel d'activité), and consolidated financial statements (Comptes consolidés résumés). It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2025
2025-09-30 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.